Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to  Tie-2  is a common target in medicine.

Tie signaling controls the link between endothelial cells and pericytes, but the molecular mechanism of action is still unclear. Pericyte Tie-2 controls sprouting angiogenesis in vitro sprouting and in vivo spheroid assays. Tie2 downstream signaling in pericytes involves Calpain, Akt, and FOXO3A. Ng2-Cre-driven deletion of pericyte-expressed Tie2 in mice transiently delays postnatal retinal angiogenesis. Yet, Tie-2 deletion in pericytes results in a pronounced pro-angiogenic effect leading to enhanced tumor growth. It has been found that exosomes derived from high Tie-2 cervical cancer cells induce TEMs through direct transport of Tie-2 and promote tumor angiogenesis.

Currently, various immune drugs targeting Tie-2 targets are in the updating iteration, and taking the disease alone or in combination with other products has become a new approach with remarkable achievements. The Tie-2 targets have shown important research value and application prospects in both biology and drug research and development. With further research and detection technology advances, Tie-2 target products are also essential in medical research. Alpha Lifetech can provide Tie-2 corresponding products and help each customer's research and development. Alpha Lifetech focuses on high-precision detection development and validation services to support drug screening and biosimilar discovery. Our detection methods, including ELISA, cell-based functional testing, and flow cytometry, have undergone rigorous sensitivity, specificity, and reproducibility testing. In addition to testing and development, our team also provides data analysis, scheme optimization, and cross-species reactivity testing to ensure reliable results.